We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Atossa Therapeutics Inc | NASDAQ:ATOS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.03 | 1.86% | 1.64 | 1.63 | 1.64 | 1.64 | 1.545 | 1.62 | 559,012 | 17:34:40 |
The study identifies a well-accepted epidemiology signal of COVID-19, internet searches for the loss of smell and/or taste, spiking in California the first two weeks of 2020, clearly indicating symptomatic patients in California at that time. The study also identifies about 980 deaths nationwide and 440 deaths in California in early January that were attributed to pneumonia and/or influenza but are likely to have been incorrectly diagnosed and are, with high probability, the first deaths from COVID-19 in the U.S.
“This study arose when I considered the origin of SARS-CoV-2 in Wuhan, China in early December, the rate and ease of human-to-human spread, especially in crowded indoor locations, and the expected annual year-end glut of holiday travel that the world experiences. From the perspective of the virus, there is no difference between spending 13 hours spreading from human to human in a traditional market in Wuhan or spending 13 hours traveling to LAX in California and spreading in Beverly Hills,” stated Dr. Quay. “This pandemic has provided a stark example of the unprecedented perils we have created by our modern world.”
Dr. Quay continued, “My book entitled, COVID-19 Survival Manual: A Physician’s Guide to Keep You and Your Family Healthy During the Pandemic and Beyond, will be published as an Amazon Kindle book on June 5, 2020, and will provide my blueprint for how to move beyond this pandemic safely for you and your family. Before anyone decides to return to life outside the shelter, please read my book. It might save your life!”
COVID-19 Survival Manual: A Physician’s Guide to Keep You and Your Family Healthy during the Pandemic and Beyond
This book is chock-full of lifesaving tips you can’t find anywhere else to help you and your family stay safe while sheltering-in-place, as well as how to get back to life in the coming weeks and months.
Some highlights:
It will be available on Amazon Kindle for $4.99 starting June 5. The proceeds will be shared with Team Rubicon, a non-profit organization that serves communities by mobilizing veterans to continue their service, leveraging their skills and experience to help people prepare, respond, and recover from disasters and humanitarian crises.
About Steven Quay, M.D., PhD.
Steven Quay is the founder, Chairman, and CEO of Seattle-based Atossa Therapeutics, Inc. (NASDAQ: ATOS) a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions.
Dr. Quay received his M.D., M.A. and Ph.D. from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-Massachusetts General Hospital, and was on the faculty of Stanford University School of Medicine for almost a decade. He has over 300 published contributions to medicine which have been cited over 9,700 times.
Dr. Quay has founded six pharmaceutical startups, invented seven FDA-approved medicines, and holds 87 U.S. patents. Over 80 million people have benefited from the drugs he has invented. His current passion is the prevention of the two million yearly breast cancer cases worldwide. A TEDx talk he delivered on breast cancer prevention, “How to Be Smart If You’re Dense,” has been viewed over 200,000 times.
Public Relations Contact Dunn Pellier Media | t: 323.481.2307 11620 Wilshire Blvd | 9th Floor, Los Angeles, CA 90025melissa@dunnpelliermedia.comnicole@dunnpelliermedia.com
1 Year Atossa Therapeutics Chart |
1 Month Atossa Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions